3,781 research outputs found
Silicon Detectors For P-p-bar Small-angle Physics
No full textThe use of silicon detectors in p-p small-angle physics is discussed. The performance of a set of double-sided readout silicon detectors is shown. Test beam results on the efficiency for minimum-ionizing particles, the space accuracy and the charge correlation between the ohmic and junction side of the detectors are presented. © 1989
Performance of Surface-barrier Silicon Detectors With X, Y Readout
No full textThe construction techniques of a set of surface barrier double sided readout silicon detectors are illustrated. Test beam results obtained at Fermilab with a 250 Gev π beam are reported. © 1989
Bevacizumab impairs the activity of major VEGF-carrier cells: neutrophils and platelets.
No full text
Search for narrow resonances below the Upsilon mesons
No full textWe have investigated the invariant mass spectrum of dimuons collected by the CDF experiment during the 1992-1995 run of the Fermilab Tevatron collider to improve the limit on the existence of narrow resonances set by the experiments at the SPEAR e(+)e(-) collider. In the mass range 6.3-9.0 GeV/c(2), we derive 90% upper credible limits to the ratio of the production cross section times muonic branching fraction of possible narrow resonances to that of the Upsilon(1S) meson. In this mass range, the average limit varies from 1.7 to 0.5%. This limit is much worse at the mass of 7.2 GeV/c(2) due to an excess of 250 +/- 61 events with a width consistent with the detector resolution
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients
No full textCetuximab is a human-murine chimeric monoclonal antibody to the epidermal growth factor receptor, active for advanced colorectal cancer treatment in combination with chemotherapy. Cetuximab mainly acts by inhibiting epidermal growth factor receptor-mediated pathways in cancer cells; however, in the human host, its IgG1 backbone may offer additional antitumor activity that includes FcγRs-mediated antibody-dependent cell cytotoxicity, phagocytosis, cross priming, and tumor-specific T-cell-mediated immune response. These mechanisms are still under active investigation. At this purpose, we have performed an immunologic investigation in advanced colon cancer patients enrolled in an ongoing phase II trial aimed to test the toxicity and the biological and antitumor activity of a novel biochemotherapy regimen combining polychemotherapy with gemcitabine, irinotecan, levofolinic acid, and fluorouracil with cetuximab and with subcutaneous low-dose metronomic aldesleukin (GILFICet regimen). The peripheral blood mononuclear cells of the first 20 patients enrolled in the GILFICet trial were collected at baseline and after 6 treatment cycles and examined for immune-phenotype change by flow cytometry. Colon cancer-specific T-cell lines were also generated ex vivo from these samples and subsequently characterized for immune phenotype, functional activity, and antigen specificity. We found a treatment-related increase of circulating dendritic cells, natural killer cells, central memory T cells, and activated T cells with a T-helper 1 (Th1)-cytotoxic phenotype. In addition, the ex-vivo characterization of antigen-specific T cells derived from the treated patients revealed a significant increase in proliferating cytotoxic T-lymphocyte precursors specific for carcinoembryonic antigen and thymidylate synthase derivative epitope peptides. On these basis, we concluded that the GILFICet regimen exerts substantial immune-modulating activity that significantly affects tumor antigen-specific T-cell compartment with potential antitumor activity. © 2012 by Lippincott Williams & Wilkins
- …
